65,437 trials
Chronic Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 100 percentage of participants
Fabry Disease
Primary: Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium — 18.8; 33.3; 75; 80 Percentage of participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline. — -0.9; -1.0 Percent (%) glycosylated haemoglobin
Innate Immune Response
Primary: Cytokine Production Measured by ELISA Compared to Baseline — 1.2 ratio
Renal Cell Carcinoma
Primary: Progression Free Survival First-Line (PFS 1-L) — 7.85; 10.71 Months
Ultrasound-guided Internal Jugular Cannulation · Central Venous Access Complications
Primary: Cannulation Success — 73; 71; 68 participants
Respiratory Failure
Primary: Duration of Mechanical Ventilation — 129.5; 208.1 hours
Stroke
Primary: Feasibility and Tolerability of External Counterpulsation — 12; 9 participants
Hepatitis C, Chronic
Primary: Percentage of Participants in Korea and Taiwan With Sustained Virologic Response (SVR) at Follow-Up Week 24 - Full Analysis Set (FAS) Population — 60.90; 26.15…
Pain
Primary: Maximum Plasma Concentration (Cmax) — 408 ng/mL
Neonatal Anemia
Primary: Neonatal Hemoglobin Level — 11.86; 11.95 gram%
Aging
Primary: Quality of Movements' Total Average Score — 87 percentage of quality of movements
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Prediabetes · Metabolic Syndrome
Primary: Change in Weight — -13.9; -11.8 pounds
Peroxisome Biogenesis Disorders
Primary: Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid — 0.180; 0.188 ratio